314 related articles for article (PubMed ID: 28804849)
21. Identification of peptide antagonists to glycoprotein Ibalpha that selectively inhibit von Willebrand factor dependent platelet aggregation.
Benard SA; Smith TM; Cunningham K; Jacob J; DeSilva T; Lin L; Shaw GD; Kriz R; Kelleher KS
Biochemistry; 2008 Apr; 47(16):4674-82. PubMed ID: 18363340
[TBL] [Abstract][Full Text] [Related]
22. Platelet-collagen interaction: inhibition by ristocetin and enhancement by von Willebrand factor-platelet binding.
LaDuca FM; Bettigole RE; Bell WR; Robson EB
Blood; 1986 Oct; 68(4):927-37. PubMed ID: 3489493
[TBL] [Abstract][Full Text] [Related]
23. Diagnosis or Exclusion of von Willebrand Disease Using Laboratory Testing.
Favaloro EJ
Methods Mol Biol; 2017; 1646():391-402. PubMed ID: 28804843
[TBL] [Abstract][Full Text] [Related]
24. [Type 2B and pseudo type 2B Von Willebrand disease; a report of three cases].
Guermazi S; Conard J; Samama MM; Dellagi K
Pathol Biol (Paris); 2006 Apr; 54(3):159-65. PubMed ID: 16176858
[TBL] [Abstract][Full Text] [Related]
25. Laboratory Testing for von Willebrand Factor Activity by Glycoprotein Ib Binding Assays (VWF:GPIb).
Patzke J; Favaloro EJ
Methods Mol Biol; 2017; 1646():453-460. PubMed ID: 28804847
[TBL] [Abstract][Full Text] [Related]
26. Phenotype changes resulting in high-affinity binding of von Willebrand factor to recombinant glycoprotein Ib-IX: analysis of the platelet-type von Willebrand disease mutations.
Tait AS; Cranmer SL; Jackson SP; Dawes IW; Chong BH
Blood; 2001 Sep; 98(6):1812-8. PubMed ID: 11535515
[TBL] [Abstract][Full Text] [Related]
27. Technological advances in diagnostic testing for von Willebrand disease: new approaches and challenges.
Hayward CP; Moffat KA; Graf L
Int J Lab Hematol; 2014 Jun; 36(3):334-40. PubMed ID: 24750680
[TBL] [Abstract][Full Text] [Related]
28. A new case of platelet-type von Willebrand disease supports the recent findings of gain-of-function GP1BA variants outside the C-terminal disulphide loop enhances affinity for von Willebrand factor.
Monteiro C; Gonçalves A; Pereira M; Lau C; Morais S; Santos R
Br J Haematol; 2023 Nov; 203(4):673-677. PubMed ID: 37592722
[TBL] [Abstract][Full Text] [Related]
29. Biochemical characterization of a recombinant von Willebrand factor (VWF) with combined type 2B and type 1 defects in the VWF gene in two patients with a type 2A phenotype of von Willebrand disease.
Baronciani L; Federici AB; Cozzi G; Canciani MT; Mannucci PM
J Thromb Haemost; 2007 Feb; 5(2):282-8. PubMed ID: 17155947
[TBL] [Abstract][Full Text] [Related]
30. A novel platelet-type von Willebrand disease mutation (GP1BA p.Met255Ile) associated with type 2B "Malmö/New York" von Willebrand disease.
Lavenu-Bombled C; Guitton C; Dupuis A; Baas MJ; Desconclois C; Dreyfus M; Li R; Caron C; Gachet C; Fressinaud E; Lanza F
Thromb Haemost; 2016 Nov; 116(6):1070-1078. PubMed ID: 27683759
[TBL] [Abstract][Full Text] [Related]
31. Defective interaction between von Willebrand factor and platelet glycoprotein Ib--a familial study of peripheral arterial occlusive disease.
Kauhanen P; Beer JH; Lassila R
Thromb Haemost; 1997 May; 77(5):849-55. PubMed ID: 9184391
[TBL] [Abstract][Full Text] [Related]
32. Platelet activation and aggregation induced by recombinant von Willebrand factors reproducing four type 2B von Willebrand disease missense mutations.
de Romeuf C; Hilbert L; Mazurier C
Thromb Haemost; 1998 Jan; 79(1):211-6. PubMed ID: 9459349
[TBL] [Abstract][Full Text] [Related]
33. Distinct abnormalities in the interaction of purified types IIA and IIB von Willebrand factor with the two platelet binding sites, glycoprotein complexes Ib-IX and IIb-IIIa.
De Marco L; Mazzucato M; De Roia D; Casonato A; Federici AB; Girolami A; Ruggeri ZM
J Clin Invest; 1990 Sep; 86(3):785-92. PubMed ID: 2394830
[TBL] [Abstract][Full Text] [Related]
34. High resolution multimer analysis and the PFA-100 platelet function analyser can detect von Willebrand disease type 2A without a pathological ratio of ristocetin cofactor activity and von Willebrand antigen level.
Weiss DR; Strasser EF; Ringwald J; Zimmermann R; Eckstein R
Clin Lab; 2012; 58(11-12):1203-9. PubMed ID: 23289190
[TBL] [Abstract][Full Text] [Related]
35. Modulation by heparin of the interaction of the A1 domain of Von Willebrand factor with glycoprotein Ib.
Perrault C; Ajzenberg N; Legendre P; Rastegar-Lari G; Meyer D; Lopez JA; Baruch D
Blood; 1999 Dec; 94(12):4186-94. PubMed ID: 10590063
[TBL] [Abstract][Full Text] [Related]
36. Molecular cloning and characterization of rhesus monkey platelet glycoprotein Ibα, a major ligand-binding subunit of GPIb-IX-V complex.
Qiao J; Shen Y; Shi M; Lu Y; Cheng J; Chen Y
Thromb Res; 2014 May; 133(5):817-25. PubMed ID: 24560895
[TBL] [Abstract][Full Text] [Related]
37. Clinical significance of inhibitors in acquired von Willebrand syndrome.
Mohri H; Motomura S; Kanamori H; Matsuzaki M; Watanabe S; Maruta A; Kodama F; Okubo T
Blood; 1998 May; 91(10):3623-9. PubMed ID: 9572997
[TBL] [Abstract][Full Text] [Related]
38. Plasma glycocalicin as a source of GPIbalpha in the von Willebrand factor ristocetin cofactor ELISA.
Vanhoorelbeke K; Pareyn I; Schlammadinger A; Vauterin S; Hoylaerts MF; Arnout J; Deckmyn H
Thromb Haemost; 2005 Jan; 93(1):165-71. PubMed ID: 15630508
[TBL] [Abstract][Full Text] [Related]
39. Identification of p.W246L as a novel mutation in the GP1BA gene responsible for platelet-type von Willebrand disease.
Woods AI; Sanchez-Luceros A; Bermejo E; Paiva J; Alberto MF; Grosso SH; Kempfer AC; Lazzari MA
Semin Thromb Hemost; 2014 Mar; 40(2):151-60. PubMed ID: 24474090
[TBL] [Abstract][Full Text] [Related]
40. Laboratory diagnosis and molecular classification of von Willebrand disease.
Gadisseur A; Hermans C; Berneman Z; Schroyens W; Deckmyn H; Michiels JJ
Acta Haematol; 2009; 121(2-3):71-84. PubMed ID: 19506352
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
